Summary
Fifty-five patients with metastatic non-small cell lung cancer (NSCLC) were entered into this phase II randomized study for evaluating three new agents: gallium nitrate, amonafide and teniposide. The patients had to have ECOG performance status 0 or 1, no prior chemotherapy, and adequate hematological, hepatic and renal functions. Forty-seven patients were eligible and evaluable. Fourteen were randomized to receive gallium nitrate, 18 to amonafide and 15 to teniposide. Seventy-four percent of eligible patients were male. The majority of patients (89%) had an ECOG performance status 1. ECOG grade 4 toxicity occurred twice in patients on gallium nitrate, seven times on amonafide and 18 times on teniposide. The cause of death was attributed to amonafide in one patient (from sepsis) and to teniposide in two patients (due to infection and leukopenia). There was no objective response in all the patients entered. The overall survival times ranged from 2 weeks to 156 weeks with a median of 23 weeks. There were no survival differences among the three treatment arms. We conclude that gallium nitrate, amonafide and teniposide are inactive in metastatic NSCLC and do not warrant any further testing in this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boring CC, Squires TS, Tong T, Montgomery S: Cancer Statistics, 1994. CA Cancer J Clin 44:7–26, 1994
Idhe DC, Minna JD: Non-small cell lung cancer. II. Treatment. Curr Probl Cancer 15:105–154, 1991
Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AMet al.: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer (NSCLC): Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641, 1988
Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp Eet al.: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19–21, 1993
Waalkes TP, Sanders K, Smith RG, Adamson RH: DNA polymerases of walker 256 carcinosarcoma. Cancer Res 34:385–391, 1974
Hayes RL, Nelson B, Swartzendruber DC, Carlton JE, Byrd BL: Gallium-67 localization in rat and mouse tumors. Science 167:289–290, 1970
Larson SM, Rasey JS, Allen DR, Nelson NJ, Brunbaum Z, Harp GD, Williams DL: Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Nat Cancer Inst 64:41–53, 1980
Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA:In vitro toxicity and DNA cleavage capacity of benzisoquinolinedione (Nafidemide: NSC 308847) in human leukemia. Cancer Res 47:1040–1044, 1987
Adamson RH, Canellos GP, Sieber SM: Studies on the antitumor activity of gallium nitrate (NSC 15200) and other group IIIa metal salts. Cancer Chemother Rep 59:599–610, 1975
Krakoff IH, Newman RA, Goldberg RS: Clinical toxicologic and pharmacologicstudies of gallium nitrate. Cancer 44:1722–1727, 1979
O'Dwyer PJ, Alonso MT, Leyland-Jones B, Marsoni S: Teniposide: A review of 12 years of experience. Cancer Treat Rep 68:1455–1466, 1984
Warrell RP Jr, Coonley CJ, Straus DJ, Young CW: Treatment of patients with advanced malignant lymphoma using gallium nitrate as a seven-day continuous infusion. Cancer 51:1982–1987, 1983
Giaccone G, Donadio M, Ferrati P, Bonardi G, Ciuffreda L, Bagatella M, Calciati A: Teniposide in the treatment of non-small cell lung carcinoma. Cancer Treat Rep 71:83–88, 1987
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982
Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Statis Assoc 58:457–581, 1958
Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB: Phase I study of amonafide dosing based on an acetylator phenotype. Cancer Res 53 (suppl 10):2304–2308, 1993
Author information
Authors and Affiliations
Additional information
The contents of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
Rights and permissions
About this article
Cite this article
Chang, A.Y., Nora Tu, Z., Smith, J.L. et al. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. Invest New Drugs 13, 137–141 (1995). https://doi.org/10.1007/BF00872862
Issue Date:
DOI: https://doi.org/10.1007/BF00872862